SPY425.26+0.95 0.22%
DIA344.30-0.82 -0.24%
IXIC14,174.14+104.72 0.74%

Matinas BioPharma Hldgs's Earnings: A Preview

Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Monday, May 10. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.

05/07/2021 10:09

Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Monday, May 10. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Matinas BioPharma Hldgs's per-share loss will be near $0.03 on sales of $20.00 thousand, according to Wall Street analysts. In the same quarter last year, Matinas BioPharma Hldgs reported EPS of $0.03 on revenue of $0.00.

Why Analyst Estimates And Earnings Surprises Are Important

Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.

If the company were to post earnings in line with the consensus estimate when it reports Monday, EPS would be down 0%. Revenue would be unchanged from the year-ago period. Here is how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter Q4 2021 Q3 2020 Q2 2020 Q1 2020
EPS Estimate -0.03 -0.03 -0.03 -0.03
EPS Actual -0.03 -0.03 -0.03 -0.03
Revenue Estimate 1.02 M 20.00 K 20.00 K 30.00 K
Revenue Actual 62.50 K 95.83 K 0 0

eps graph

Stock Performance

Over the last 52-week period, shares are up 4.1%. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Do not be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 08:00:00 ET and can be accessed here.